Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
Identification of Selective Inhibitors of the Potassium Channel Kv1.1-1.2((3)) by High-Throughput Virtual Screening and Automated Patch Clamp.
Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy.
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.
Bruxism and temporal bone hypermobility in patients with multiple sclerosis.
Transverse myelitis -- a review of the presentation, diagnosis, and initial management.
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
Prospective memory, emotional valence, and multiple sclerosis.
Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells.
Stress signaling etches heritable marks on chromatin.
Peripheral and Central Nervous System Drugs Advisory Committee Meeting: Alemtuzumab (BLA 103948\5139) Background Package
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.
Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome.
Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.
Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis.
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
Embryonic stem cell lines derived from human blastocysts.

Pages